OpenAlex
PricingAboutJobs
Log inGet started
Work

Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease

HTML

Year: 2022
Type: article
Source: Neurology
DOI: 10.1212/wnl.0000000000013314
Authors: Melanie D. Whittington, Jonathan D. Campbell, David Rind, Noemi Fluetsch, Grace A. Lin, Steven D. Pearson
Institutions: Institute for Clinical and Economic Review, University of California, San Francisco
Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life
Subfield: Economics and Econometrics
Field: Economics, Econometrics and Finance
Domain: Social Sciences
Keywords: aducanumab, Alzheimer's disease, cost-effectiveness, value-based pricing, drug pricing, incremental cost-effectiveness ratio, quality-adjusted life years, Markov model, societal perspective, threshold analysis, early Alzheimer's disease, accelerated approval, supportive care, health technology assessment, drug reimbursement decision-making
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W4205869346
FWCI: 7.644
Cites: 13
Cited by: 58
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security